Cytarabine

CHEMBL803 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
243.2 g/mol
LogP
-2.1
Phase
4

A pyrimidine nucleoside analogue that interferes with DNA synthesis by inhibiting DNA polymerase, used primarily to treat acute myeloid leukemia and other hematologic malignancies. It is often given in high-dose regimens and can cause cerebellar toxicity.

Молекулярная масса

243,2200 g/mol

LogP

-2,10

TPSA

129,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Механизм действия

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1

InChI

InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

Molecular Formula

C9H13N3O5

HBD / HBA

4 / 5

Вращаемые Связи

2

Тяжёлые Атомы

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A pyrimidine nucleoside analogue that interferes with DNA synthesis by inhibiting DNA polymerase, used primarily to treat acute myeloid leukemia and other hematologic malignancies. It is often given in high-dose regimens and can cause cerebellar toxicity.

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Yes, Cytarabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL803. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6253. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.